Remote coaching sessions to support the mental and emotional health of informal multiple sclerosis (MS) caregivers, coupled with online…
Articles by Andrea Lobo, PhD
Ocrevus (ocrelizumab) did not significantly reduce the number or volume of inflammatory lesions in the meninges in people with…
MediciNova announced the approval of a European patent covering the use of ibudilast (MN-166) in combination with…
Enrollment is nearly complete in a clinical trial of the Scone neuromodulation device in treating neurogenic, or overactive, bladder…
The U.S. Food and Drug Administration (FDA) has placed a partial hold on Genentech’s ongoing Phase 3 clinical trials testing…
Higher blood levels of macrophage migration inhibitory factor (MIF), a molecule involved in inflammation, may predict a faster rate of…
EBV-001, a vaccine candidate being developed by EBViously to target the Epstein-Barr virus (EBV), triggered the production of potent…
Tiziana Life Sciences has dosed four new participants in an expanded access program investigating its foralumab nasal spray…
The U.S. Food and Drug Administration (FDA) has cleared BrainSpec Core, a platform that performs non-invasive measurements of brain chemistry,…
Certain clinical attributes of disease-modifying therapies (DMTs), such as safety and the medication’s impact on risk of relapse and disability…
Supplementation with coconut oil and the green tea component epigallocatechin gallate (EGCG) significantly reduces the levels of fatty molecules called…
A commercial probiotic supplement containing the yeast Saccharomyces boulardii significantly eased pain and fatigue, and improved mental health and quality…
A test called Elecsys NfL — developed by Roche to measure blood levels of the nerve damage biomarker neurofilament…
A Phase 1 clinical trial evaluating LPX-TI641, Lapix Therapeutics‘ experimental therapy for multiple sclerosis (MS) and other autoimmune…
More than three-quarters of people with relapsing forms of multiple sclerosis (MS) who received Zeposia (ozanimod) in the…
The Accelerated Cure Project for Multiple Sclerosis and the Arab Board for Clinical Research have partnered with the Association…
Heligenics has discovered a number of variations in the interferon beta 1 (IFNB1) gene that may markedly improve the…
Tiziana Life Sciences has started to recruit clinical sites for a Phase 2a clinical trial that will investigate its…
The European Commission has approved Tyruko (natalizumab), the first biosimilar of Tysabri, for the treatment of adults with…
Anokion has finished enrolling patients in the second part of its Phase 1 clinical trial investigating ANK-700 for…
Imcyse has completed patient enrollment and initial dosing in a Phase 1 clinical trial evaluating IMCY-0141, its next-generation immunotherapy,…
Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple…
Octave Bioscience was selected as a finalist in this year’s Innovation by Design Awards in recognition of the platform…
Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS)…
Neuro Night, a philanthropic event set for October in Scottsdale, Arizona, is raising funds for the Barrow Neurological Institute…
Treatment with Mavenclad (cladribine), an approved short-course oral therapy for relapsing forms of multiple sclerosis (MS), significantly reduced…
A web-based wellness intervention program that educated multiple sclerosis (MS) patients on dietary plans, stress management, sleep, and exercise…
People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of…
Icometrix‘s quantification software for brain MRI scans has received a Current Procedural Terminology (CPT) III code, a temporary code…
The director of the Multiple Sclerosis Center of Catalonia (CEMCAT) has been recognized with the 2023 Charcot Award, a…